Clinical trial
Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and…
NCT00239252 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00239252 |
|---|---|
| Title | Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | Interferon alfacon-1 |
| First posted | Oct 17, 2005 |
| Last update posted | Aug 26, 2014 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: